Search

Fluorescence-based techniques are prevalent in studies of nanomedicine-targeting to cells and tissues. However, fluorescence-based studies are rarely quantitative, thus prohibiting direct comparisons of nanomedicine-performance across studies. With this Commentary , we aim to provoke critical thinking about experimental design by treating some often-overlooked pitfalls in 'quantitative' fluorescence-based experimentation. Focusing on fluorescence-labeled nanoparticles, we cover mechanisms like solvent-interactions and fluorophore-dissociation, which disqualify the assumption that ' a higher fluorescence readout ' translates directly to ' a better targeting efficacy '. With departure in recent literature, we propose guidelines for circumventing these pitfalls in studies of tissue-accumulation and cell-uptake, thus covering fluorescence-based techniques like bulk solution fluorescence measurements, fluorescence microscopy, flow cytometry, and infrared fluorescence imaging. With this, we hope to lay a foundation for more 'quantitative thinking' during experimental design, enabling (for example) the estimation and reporting of actual numbers of fluorescent nanoparticles accumulated in cells and organs. [Display omitted] • Stresses the importance of more quantitative approaches in fluorescence-based nanomedicine studies • Provides a brief introduction to some fundamental principles of fluorescence in simple language • Treats fluorescence-based measurements in bulk solution, microscopy, flow cytometry and tissue/body imaging • Highlights often-overlooked challenges related to interactions between fluorophores and the biological environment • Presents strategies toward counting actual numbers of nanoparticles in cells and organs [ABSTRACT FROM AUTHOR]

[Display omitted] • Lipidating salmon calcitonin (sCal) alters its biophysical characteristics, including oligomer size, hydrophobicity and membrane activity. • Fluorescent imaging of single GUVs determines peptide mediated reporter dye influx behavior as either graded or All-or-None mechanism. • Modulating the number of hydrocarbons constituting the lipidation moieties determines the membrane permeation mechanism. • By increasing the lipid chain length lipidated of sCal goes from displaying smaller membrane perturbations to a peptide pore formation mechanism. • Effective membrane translocation of lipidated salmon calcitonin requires a peptide mediated pore forming mechanism. A widespread strategy to increase the transport of therapeutic peptides across cellular membranes has been to attach lipid moieties to the peptide backbone (lipidation) to enhance their intrinsic membrane interaction. Efforts in vitro and in vivo investigating the correlation between lipidation characteristics and peptide membrane translocation efficiency have traditionally relied on end-point read-out assays and trial-and-error-based optimization strategies. Consequently, the molecular details of how therapeutic peptide lipidation affects it's membrane permeation and translocation mechanisms remain unresolved. Here we employed salmon calcitonin as a model therapeutic peptide and synthesized nine double lipidated analogs with varying lipid chain lengths. We used single giant unilamellar vesicle (GUV) calcein influx time-lapse fluorescence microscopy to determine how tuning the lipidation length can lead to an All-or-None GUV filling mechanism, indicative of a peptide mediated pore formation. Finally, we used a GUVs-containing-inner-GUVs assay to demonstrate that only peptide analogs capable of inducing pore formation show efficient membrane translocation. Our data provided the first mechanistic details on how therapeutic peptide lipidation affects their membrane perturbation mechanism and demonstrated that fine-tuning lipidation parameters could induce an intrinsic pore-forming capability. These insights and the microscopy based workflow introduced for investigating structure–function relations could be pivotal for optimizing future peptide design strategies. [ABSTRACT FROM AUTHOR]

Membrane-active peptides (MAPs) have several potential therapeutic uses, including as antimicrobial drugs. Many traditional methods used to evaluate the membrane interactions of MAPs have limited applicability. Low-throughput methods, such as microscopy, provide detailed information but often rely on fluorophore-labeled MAPs, and high-throughput assays, such as the calcein release assay, cannot assess the mechanism behind the disruption of vesicular-based lipid membranes. Here we present a flow cytometric assay that provides detailed information about the peptide-lipid membrane interactions on single artificial lipid vesicles while being high-throughput (1000–2000 vesicles/s) and based on label-free MAPs. We synthesized and investigated six MAPs with different modes of action to evaluate the versatility of the assay. The assay is based on the flow cytometric readouts from artificial lipid vesicles, including the fluorescence from membrane-anchored and core-encapsulated fluorophores, and the vesicle concentration. From these parameters, we were able to distinguish between MAPs that induce vesicle solubilization, permeation (pores/membrane distortion), and aggregation or fusion. Our flow cytometry findings have been verified by traditional methods, including the calcein release assay, dynamic light scattering, and fluorescence microscopy on giant unilamellar vesicles. We envision that the presented flow cytometric assay can be used for various types of peptide-lipid membrane studies, e.g. to identify new antibiotics. Moreover, the assay can easily be expanded to derive additional valuable information. [Display omitted] • Developed a novel assay to study the modes of action of membrane-active peptides. • Our flow cytometric high-throughput assay relies on label-free peptides. • Fluorescence microscopy, DLS and calcein release studies confirmed the validity of our assay. • Six very different membrane-active peptides were evaluated in our assay. [ABSTRACT FROM AUTHOR]